<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-598
Date of Submission: 2024-08-14

This report was submitted by a Physician from Moore Ltd Medical Center concerning patient ANON-PX-6116. The subject is an adult other with a significant medical history including type 2 diabetes, atrial fibrillation, migraines, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Intravenous route at a dosage of 310mg, initiated on 2024-07-09 for Hypertension with the course ongoing; Gabapentin administered via the Topical route at a dosage of 119mg, initiated on 2024-07-09 for Neuropathic pain with the course ongoing.

On approximately 2024-08-03, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Anaphylaxis, Maculopapular Rash, Hepatotoxicity. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed simply and advised traditional. The current patient status regarding this symptom is 'Fatal'. The Anaphylaxis was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Hepatotoxicity was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed social and advised attorney. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Nor as machine Congress audience make know. Hope card middle quite may lead. Because nearly throughout he alone.</data>
report_id: ADR-2024-598
report_date: '2024-08-14'
patient_details:
  patient_id: ANON-PX-6116
  gender: Other
  relevant_history:
  - type 2 diabetes
  - atrial fibrillation
  - migraines
  - seasonal allergies
suspected_drugs:
- drug_name: Lisinopril
  dosage: 310mg
  route_of_administration: Intravenous
  start_date: '2024-07-09'
  indication_for_use: Hypertension
  drug_class: ACE inhibitor
- drug_name: Gabapentin
  dosage: 119mg
  route_of_administration: Topical
  start_date: '2024-07-09'
  indication_for_use: Neuropathic pain
adverse_reactions:
- symptom_name: Angioedema
  onset_date: '2024-08-03'
  severity: Life-threatening
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed simply and advised traditional.
- symptom_name: Anaphylaxis
  onset_date: '2024-08-03'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
- symptom_name: Maculopapular Rash
  onset_date: '2024-08-03'
  severity: Severe
  outcome: Recovered
  intervention_required: false
- symptom_name: Hepatotoxicity
  onset_date: '2024-08-03'
  severity: Severe
  outcome: Unknown
  intervention_required: true
  intervention_details: Prescribed social and advised attorney.
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Positive dechallenge
  naranjo_score: 1
reporting_facility: Moore Ltd Medical Center
reporter_type: Physician
notes: Nor as machine Congress audience make know. Hope card middle quite may lead.
  Because nearly throughout he alone.
